
    
      Approximately 478 participants will be randomized 1:1 to Arm A (B-Vd) or Arm B (D-Vd).
      Treatment will continue in both arms until progressive disease, death, unacceptable toxicity,
      withdrawal of consent or end of study, whichever occurs first.
    
  